肿瘤浸润 B 细胞抑制鼻咽癌转移
Tumor-infiltrating B cells inhibit nasopharyngeal carcinoma metastasis.
本研究表明,TIL-B在NPC的抗肿瘤免疫中发挥重要的调节作用,并提示其治疗潜力,为开发基于B细胞或靶向TLS的免疫治疗策略提供了依据。
英文原题:Prognostic markers compared to CD3+TIL in locally advanced nasopharyngeal carcinoma.
Prognostic markers compared to CD3+TIL in locally advanced nasopharyngeal carcinoma.
局部晚期鼻咽癌(LA-NPC)在一些地理区域更为常见,包括沙特阿拉伯。
局部晚期鼻咽癌(LA-NPC)在一些地理区域更为常见,包括沙特阿拉伯。通常,鼻咽癌采用肿瘤-淋巴结-转移(TNM)分期。然而,TNM分期不足以评估LA-NPC的预后。因此,我们回顾性分析并比较了LA-NPC患者中既往报道的若干预后因素,包括CD3+TIL(肿瘤浸润淋巴细胞)和外周血血红蛋白、EBV DNA拷贝数、白蛋白与碱性磷酸酶比值(AAPR)、中性粒细胞与淋巴细胞比值(NLR)或血小板与淋巴细胞比值(PLR)。研究队列为83例LA-NPC患者,这些患者此前因不同目的被纳入一项随机II期试验。单因素Cox回归分析显示,除低CD3+ TIL浸润外,任何受测变量与无病生存期(DFS)或总生存期(OS)均无显著相关性;低CD3+ TIL浸润与DFS(HR = 6.7,P = <.001)和OS(HR = 9.1,P = .043)显著相关。同样,在经验证的多因素Cox回归分析中,仅低CD3+ TIL与DFS(HR = 7.0,TIL的P < .001)和OS(HR = 9.4,P = .040)显著相关。在受测参数中,CD3+ TIL是接受CCRT治疗的LA-NPC患者DFS和OS的唯一独立预后标志物。本研究支持将CD3+ TIL而非其他因素用作LA-NPC的独立预后因素。
Locally advanced nasopharyngeal carcinoma (LA-NPC) is more prevalent in some geographic regions, including Saudi Arabia. Typically, Tumor-Node-Metastasis (TNM) staging is used in NPC. However, it is inadequate to assess the prognosis of LA-NPC.Therefore, we analyzed and compared several previously reported prognostic factors in LA-NPC patients, retrospectively, including CD3+tumor-infiltrating lymphocytes (TIL) and peripheral blood hemoglobin, EBV DNA copy number, ratios of albumin-to-alkaline phosphatase ratio (AAPR), neutrophils, or platelets-to-lymphocytes (NLR, PLR). The studied cohort was 83 LA-NPC patients previously recruited for a randomized phase II trial with a different aim.Univariate cox regression analysis showed no significant correlation between any of the tested variables with disease-free survival (DFS) or overall survival (OS) with the exception of low CD3+ TIL infiltration, which correlated significantly with DFS (HR = 6.7, P = <.001) and OS (HR = 9.1, P = .043). Similarly, in a validated multivariate cox regression analysis, only low CD3+ TIL correlated significantly with DFS (HR = 7.0, P < .001 for TIL) and OS (HR = 9.4, P = .040).Among tested parameters, CD3+ TIL was the only independent prognostic marker for DFS and OS in LA-NPC patients treated with CCRT. This study supports the use of CD3+TIL, over other factors, as an independent prognostic factor in LA-NPC.
MEMBER ACCOUNT
登录成功会直接打开下一页。